Organon (NYSE:OGN) has entered a strategic agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid), a first-in-class treatment for high cholesterol, across France, Denmark, Iceland, Sweden, Finland, and Norway.
The deal integrates Organon’s commercial infrastructure with Daiichi Sankyo’s cardiovascular portfolio to address "bad" cholesterol (LDL-C) in patients for whom standard statin therapies are insufficient or contraindicated.
Nilemdo® functions as an ATP-citrate lyase (ACL) inhibitor—a mechanism that blocks cholesterol production in the liver through a different pathway than statins.
A key driver of the partnership is the significant gender gap in cardiovascular treatment.
Cardiovascular disease remains the leading cause of death for women globally, yet women are 47% more likely than men to report statin intolerance.
By providing a non-statin alternative, Organon aims to capture a growing market of patients who currently lack effective options for reducing cardiovascular risk.
Under the terms of the agreement, Organon will manage distribution and promotion in the specified territories, while Daiichi Sankyo Europe remains the marketing authorization holder.
The move marks a significant step for Organon as it leverages its "Women’s Health" focus to expand into general medicine areas where female patients face unique clinical hurdles